Edgewise Therapeutics (EWTX) Cash from Operations (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Cash from Operations of 42543000.0 for Q1 2026, down 10.24% sequentially from 38592000.0 in Q4 2025, and down 12.35% YoY from 48538167.4 in Q1 2025.
Powered by 
Analysis
Edgewise Therapeutics (EWTX) Cash from Operations (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 42543000.0 in Q1 2026.
- Quarterly Cash from Operations fell 12.35% year-over-year to 42543000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 148493000.0 (down 25.53% YoY) and the FY2025 annual result came in at 143816000.0, down 31.91% from the prior year.
- Cash from Operations declined to 42543000.0 in Q1 2026 per EWTX's latest filing, from 38592000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 11855000.0 in Q4 2022 and troughed at 42543000.0 in Q1 2026.
- A 5-year average of 25880588.24 and a median of 26830000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations slumped 126.32% in 2023, then retreated 0.47% in 2024.
- Over 5 years, Cash from Operations stood at 11855000.0 in 2022, then plunged by 126.32% to 26830000.0 in 2023, then fell by 0.47% to 26957000.0 in 2024, then plunged by 43.16% to 38592000.0 in 2025, then retreated by 10.24% to 42543000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 42543000.0, 38592000.0, and 34776000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Edgewise Therapeutics | 4.65 Bn | 4.65 Bn | - | -42.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.47 Mn |
| Mar 31, 2026 | -42.54 Mn |
| Dec 31, 2025 | -38.59 Mn |
| Sep 30, 2025 | -34.78 Mn |
| Jun 30, 2025 | -32.58 Mn |
| Mar 31, 2025 | -37.87 Mn |
| Dec 31, 2024 | -26.96 Mn |
| Sep 30, 2024 | -27.37 Mn |
| Jun 30, 2024 | -26.10 Mn |
| Mar 31, 2024 | -28.60 Mn |
| Dec 31, 2023 | -26.83 Mn |
| Sep 30, 2023 | -22.06 Mn |
| Jun 30, 2023 | -20.23 Mn |
| Mar 31, 2023 | -22.83 Mn |
| Dec 31, 2022 | -11.86 Mn |
| Sep 30, 2022 | -11.96 Mn |
| Jun 30, 2022 | -16.25 Mn |
| Mar 31, 2022 | -12.57 Mn |
| Dec 31, 2021 | -9.42 Mn |
| Sep 30, 2021 | -8.26 Mn |